8-K: Rafael Holdings Finalizes Merger with Cyclo Therapeutics, Expanding Clinical Pipeline

Rafael Holdings completes its merger with Cyclo Therapeutics, issuing shares and warrants, and anticipates interim results from the TransportNPC Phase 3 trial in mid-2025.

Summary

• Rafael Holdings, Inc. has completed its merger with Cyclo Therapeutics, Inc. on March 25, 2025.
• Rafael issued shares of its Class B common stock to Cyclo Therapeutics shareholders, representing approximately 22% of the combined company.
• The exchange ratio was determined to be 0.3525 shares of Rafael Class B common stock for each share of Cyclo Therapeutics common stock.
• Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants.
• Markus W. Sieger, former Chairman of the Board of Cyclo, was appointed to Rafael's Board of Directors.
• The company's lead clinical asset is Trappsol Cyclo, which is being evaluated in a Phase 3 trial for Niemann-Pick Disease Type C1 (NPC1).
• Interim analysis results from the TransportNPC trial are expected in the middle of 2025.
• Cyclo Therapeutics' common stock was suspended from trading on the Nasdaq Capital Market as of March 25, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the completion of the merger, the potential of Trappsol Cyclo, and the addition of an experienced director. However, risks associated with clinical trials and competition temper the overall sentiment.

Positives

• The merger provides Rafael Holdings with a clinical-stage asset, Trappsol Cyclo, targeting a high unmet medical need.
• The TransportNPC Phase 3 trial is fully enrolled, indicating strong progress in the development of Trappsol Cyclo.
• The addition of Markus W. Sieger to the Board of Directors brings valuable experience and expertise.
• The combined company is expected to be stronger and better positioned to deliver results for shareholders and patients.

Risks

• The success of the merger depends on the successful development and commercialization of Trappsol Cyclo.
• Clinical trials are subject to inherent risks and uncertainties, and there is no guarantee that the TransportNPC trial will be successful.
• The company faces competition from other companies developing treatments for Niemann-Pick Disease Type C1.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Rafael Holdings anticipates interim results from the TransportNPC Phase 3 trial in mid-2025 and is committed to leveraging its resources to bring Trappsol Cyclo to NPC patients.

Management Comments

• Bill Conkling, President and CEO of Rafael Holdings, stated that the merger is a major step forward in their strategy to develop clinical-stage assets in areas of high unmet medical need.
• N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, expressed pleasure in announcing the completion of the merger and believes that the strength of the combined companies solidifies their commitment to deliver the results of the TransportNPC trial.

Industry Context

This merger reflects a trend in the biotechnology industry of companies combining resources to develop and commercialize promising clinical assets, particularly in areas with high unmet medical needs and rare diseases.

Comparison to Industry Standards

• The merger of Rafael Holdings and Cyclo Therapeutics is similar to other acquisitions in the biotech space where larger companies acquire smaller entities with promising drug candidates.
• Comparable companies that have pursued similar strategies include Jazz Pharmaceuticals' acquisition of Cavion and Alexion Pharmaceuticals' acquisition of Wilson Therapeutics.
• The focus on rare diseases like Niemann-Pick Disease Type C1 aligns with the industry trend of developing orphan drugs, which often receive regulatory incentives and market exclusivity.

Management Changes

Stakeholder Impact

• Shareholders of Cyclo Therapeutics received shares of Rafael Holdings, impacting their ownership and investment.
• Patients with Niemann-Pick Disease Type C1 may benefit from the potential development of Trappsol Cyclo.
• Employees of Cyclo Therapeutics are now part of Rafael Holdings, impacting their employment and career opportunities.

Next Steps

• Await interim analysis results from the TransportNPC Phase 3 trial in mid-2025.
• Seek approval for listing warrants on the NYSE American, expected on or about March 31, 2025.
• File financial statements and pro forma financial information by amendment to the Current Report on Form 8-K within 71 calendar days.

Key Dates

Keywords

Merger, Acquisition, Rafael Holdings, Cyclo Therapeutics, Trappsol Cyclo, Niemann-Pick Disease Type C1, TransportNPC, Clinical Trial, Biotechnology, Pharmaceuticals